Renowned Diabetes Authority Dr. William Polonsky Joins LabStyle Innovations Medical/Scientific Advisory Board

CAESAREA, Israel, April 2, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario Diabetes Management Solution, today announced the appointment of Dr. William Polonsky to its Scientific/Medical Advisory Board.

Dr. Polonsky is a well-known author on the subject of living with and managing diabetes, and an internationally-recognized expert on the behavioral aspects of diabetes. He will advise the company on patient and professional needs and product usage, reflecting upon his extensive experience helping people and professionals better manage diabetes and what he coined 'diabetes burnout'.

Early during his career at the Joslin Diabetes Center, Dr. Polonsky realized the need to support the difficult emotional and behavioral challenges that people with diabetes experience on a daily basis. Through his establishment of the BDI Behavioral Diabetes Institute (BDI) in 2003, Dr. Polonsky developed strategies and processes to build diabetes support and educational programs for diabetes self-management for people living with diabetes and those who support them, as well as training programs for healthcare professionals. To this day, the BDI Institute conducts a wide range of professional and scientific research on the various aspects of living with and treating diabetes.

"Dr. Polonsky has dedicated his career to understanding and improving the management of diabetes", said Erez Raphael, LabStyle's President and Chief Executive Officer. "We have designed Dario to help make the daily struggle of diabetes easier for patients around the world, and Dr. Polonsky brings decades of relevant clinical experience and research to the Dario team, helping us provide the right tools, knowledge and motivation to assist people with diabetes and their support teams at home and in the clinics. We very much looking forward to working with him."

"LabStyle Innovations, and the Dario solution for diabetes specifically, reflects the critical value in combining personalized knowledge and motivation with medical tools to help people better manage diabetes" said Dr. Polonsky. "It is my honor to join the LabStyle Innovations Medical/Scientific Advisory Board, and I look forward to helping this innovative company make life easier for millions of people with diabetes."

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario Diabetes Management Solution. Dario received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario personalized smart meter in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: and

About Dr. William Polonsky, PhD.

Dr. Polonsky is an internationally recognized expert in the behavioral aspects of diabetes management. He co-founded the Behavioral Diabetes Institute to advance research and develop effective programs to serve the often unrecognized emotional needs of people with diabetes. He is author of numerous books, including the famed Diabetes Burnout: What to Do When You Can't Take It Anymore.

A licensed Clinical Psychologist and Certified Diabetes Educator, he has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators. He has also served on the editorial boards of Diabetes Care, Diabetes Forecast, Clinical Diabetes, Diabetes Self-Management and Diabetes Health.

Dr. Polonsky's recent research has focused on topics including quality of life in diabetes, diabetes-related distress and depression, hypoglycemic fear, blood glucose monitoring behavior and attitudes in people living with diabetes, group-based behavior change programs, and emotional and behavioral responses to the diagnosis of diabetes.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, results of the Company's association with Dr. Polonsky) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

© LabStyle Innovations Corp. All rights reserved.


Brenda Zeitlin

Investor Relations


Booke and Company, Inc.

LabStyle Innovations


[email protected]

[email protected]

SOURCE LabStyle Innovations Corp.